-
Mashup Score: 7Transplant without salvage: cut out the middleman - 24 day(s) ago
In this issue of The Lancet Haematology, Matthias Stelljes and colleagues1 present a compelling exploration of an approach to allogeneic haematopoietic stem-cell transplantation (HSCT) in patients at high risk of relapse or induction-refractory acute myeloid leukaemia. This concept is in stark contrast with the long-upheld orthodoxy of using varying regimens of salvage chemotherapy to induce remission or a morphological leukaemia-free state before transplantation.2 These approaches, while considered to be the standard of care in most institutions, are associated with substantial morbidity, particularly when conventional chemotherapy is used.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Findings from SELECT-AML-1 support the potential benefit of tamibarotene in those with acute myeloid leukemia harboring RARA gene overexpression.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Voruciclib Plus Venetoclax Shows Early Activity, Tolerability in Relapsed/Refractory AML - 30 day(s) ago
Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Voruciclib Plus Venetoclax Shows Early Activity, Tolerability in Relapsed/Refractory AML - 1 month(s) ago
Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Voruciclib Plus Venetoclax Shows Early Activity, Tolerability in Relapsed/Refractory AML - 1 month(s) ago
Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Voruciclib Plus Venetoclax Shows Early Activity, Tolerability in Relapsed/Refractory AML - 1 month(s) ago
Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study - 1 month(s) ago
Pivekimab sunirine showed single-agent activity across multiple doses, with a recommended phase 2 dose of 0·045 mg/kg once every 3 weeks. These findings led to a phase 1b/2 study of pivekimab sunirine plus azacitidine and venetoclax in patients with CD123-positive acute myeloid leukaemia.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Unpacking the Significance of Liso-Cel’s FDA Approval and Continued Investigation in CLL/SLL - 1 month(s) ago
Saad J. Kenderian, MB, CHB, expands on the significance of liso-cel’s approval in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 68Novel Biomarkers and Molecular Targets in ALL - 1 month(s) ago
Current Hematologic Malignancy Reports – Acute lymphoblastic leukemia (ALL) is a widely heterogeneous disease in terms of genomic alterations, treatment options, and prognosis. While ALL is…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Dr Jabbour on the Significance of the FDA Approval of Ponatinib Plus Chemo for PH+ ALL - 2 month(s) ago
Elias Jabbour, MD, discusses the FDA approval of ponatinib plus chemotherapy for Philadelphia chromosome–positive acute lymphoblastic leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
"The study offers valuable insights and could prompt a reassessment of the requirement to achieve remissions before transplantation when safer and more effective methods of salvage are unavailable" Comment by Arjun Datt Law & Jonas I Mattsson #leusm https://t.co/mu8UyjK3U1